Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
Special Dividend Data
The current last sale of $3.1045 is 14.98% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 3.17||$ 46|
|Low:||$ 2.67||$ 2.70|
Company Description (as filed with the SEC)
We are a commercial-stage pharmaceutical company focused on developing and commercializing differentiated anti-infectives for the hospital and select non-hospital, or community, settings that address the need for effective treatments for infections due to resistant gram-negative and gram-positive bacteria. We currently market four antibiotics to treat a variety of infections caused by these resistant bacteria. Melinta was formed as a private company in October 2000, and operated using funds from licensing and collaboration agreements, private equity placements and debt until 2017. We received approval for our first drug, Baxdela® (delafloxacin), in June 2017. On November 3, 2017, we completed a reverse merger with Cempra, Inc., the result of which the registrant Cempra, Inc. was re-named Melinta Therapeutics, Inc. and we became a publicly-traded company. ... More ...
Nasdaq Official Price
May 21, 2019
May 20, 2019